Side-by-side · Research reference

PancragenvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/39 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

Pancragen

Retatrutide

Primary target

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

Yes — preserves physiological glucose-insulin response

—

Origin

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

Pancragen

Retatrutide

Primate dose (rhesus macaque)

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

—

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

—

Route

IntramuscularGoncharova 2015

—

Frequency

Once daily for 10 daysGoncharova 2014

Once weekly

Treatment cycle

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

—

Evidence basis

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Diabetes model

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

—

Standard dose

—

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Duration

—

Indefinite for chronic indication (presumed)

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

04Side Effects & Safety

Parameter

Pancragen

Retatrutide

Reported adverse events

None documented in primate studies

—

Tolerability

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

—

Human safety data

No published human trials; clinical use limited to Russian gerontology protocols

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

Pancragen

—

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

Pancragen

Retatrutide

1. Reconstitution

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Route

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

No specific timing constraints documented. Administered once daily in primate protocols.

Once weekly, same day.

4. Cycle structure

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

Refrigerate 2–8 °C. Light-protected.

5. Needle

—

27–31G, 4–8 mm insulin syringe.